Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study

Nicola Cherry, Division of Preventive Medicine, University of Alberta, 5-22 University Terrace, Edmonton, T6G 2T4, AB, Canada
Anil Adisesh, Division2 Division of Occupational Medicine, Department of Medicine, University of Toronto, C. David Naylor Building, 6 Queen's Park Crescent West, Toronto, M5S 3H2, ON, Canada
Igor Burstyn, Department of Environmental and Occupational Health, Drexel University, Philadelphia, 19104, PA, United States
Carmen Charlton, Alberta Precision Laboratories, 84440 112 St, Edmonton, T6G 2I2, AB, Canada
Yan Chen, Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 735, Memphis, 38105, TN, United States
Quentin Durand-Moreau, Division of Preventive Medicine, University of Alberta, 5-22 University Terrace, Edmonton, T6G 2T4, AB, Canada
France Labrèche, Research Department, Institut de recherche Robert-Sauvé en santé et en sécurité du travail, 505 de Maisonneuve Blvd, West Montreal, H3A 3C2, QC, Canada
Shannon Ruzycki, Department of Medicine, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, T2N 4N1, AB, Canada
LeeAnn Turnbull, Alberta Precision Laboratories, 84440 112 St, Edmonton, T6G 2I2, AB, Canada
Tanis Zadunayski, Division of Preventive Medicine, University of Alberta, 5-22 University Terrace, Edmonton, T6G 2T4, AB, Canada
Yutaka Yasui, Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 735, Memphis, 38105, TN, United States

Type de document

Études primaires

Année de publication

2024

Langue

Anglais

Titre de la revue

Vaccine

Première page

1168

Dernière page

1178

Résumé

Introduction: Healthcare workers (HCWs) from an interprovincial Canadian cohort gave serial blood samples to identify factors associated with anti-receptor binding domain (anti-RBD) IgG response to the SARS-CoV-2 virus. Methods: Members of the HCW cohort donated blood samples four months after their first SARS-CoV-2 immunization and again at 7, 10 and 13 months. Date and type of immunizations and dates of SARS-CoV-2 infection were collected at each of four contacts, together with information on immunologically-compromising conditions and current therapies. Blood samples were analyzed centrally for anti-RBD IgG and anti-nucleocapsid IgG (Abbott Architect, Abbott Diagnostics). Records of immunization and SARS-CoV-2 testing from public health agencies were used to assess the impact of reporting errors on estimates from the random-effects multivariable model fitted to the data. Results: 2752 of 4567 vaccinated cohort participants agreed to donate at least one blood sample. Modelling of anti-RBD IgG titer from 8903 samples showed an increase in IgG with each vaccine dose and with first infection. A decrease in IgG titer was found with the number of months since vaccination or infection, with the sharpest decline after the third dose. An immunization regime that included mRNA1273 (Moderna) resulted in higher anti-RBD IgG. Participants reporting multiple sclerosis, rheumatoid arthritis or taking selective immunosuppressants, tumor necrosis factor inhibitors, calcineurin inhibitors and antineoplastic agents had lower anti-RBD IgG. Supplementary analyses showed higher anti-RBD IgG in those reporting side-effects of vaccination, no relation of anti-RBD IgG to obesity and lower titers in women immunized in early or mid-pregnancy. Sensitivity analysis results suggested no important bias in the self-report data. Conclusion: Creation of a prospective cohort was central to the credibility of results presented here. Serial serology assessments, with longitudinal analysis, provided effect estimates with enhanced accuracy and a clearer understanding of medical and other factors affecting response to vaccination. © 2024 The Author(s)

Mots-clés

Coronavirus du SRAS 2, SARS Coronavirus 2, SARS CoV2, Immunoglobuline, Immunoglobulin, Service de santé, Health service, Personnel médical, Medical personnel, Étude de cohorte, Cohort study, Canada

Numéro de projet IRSST

n/a

Ce document n'est pas disponible pour le moment.

Partager

COinS